Business
CollPlant Announces Effectiveness of Uplisting to the Nasdaq Global Market®; Ordinary Shares Replace ADSs
REHOVOT, Israel, June 4, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, announced today the uplisting of its
About this update from Collplant Biotechnologies Ltd.
[{"type":"text","content":"REHOVOT, Israel, June 4, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, announced today the uplisting of its ordinary shares to the Nasdaq Global Select Market® effective at the open of market today, Friday, June 4, 2021.\nCollPlant's ordinary shares now trade under the Company's current ticker symbol \"CLGN\" and the Company's American Depositary Shares (ADSs) have been mandatorily cancelled and exchanged for ordinary shares at a one-for-one ratio. Shareholders holding their ADSs in book-entry or through a bank, broker, or other nominee form do not need to take any action in connection with the mandatory exchange.\n\"We are pleased to complete this important milestone and believe that our current and future shareholders will benefit from our Nasdaq Global Market® status and the transition to ordinary shares,\" stated Yehiel Tal, CollPlant CEO.\nA listing on the Nasdaq Global Market® is considered an indicator of status and success for companies that qualify for listing. Listed companies must satisfy stringent financial, liquidity and corporate governance requirements, both initially and on an ongoing basis.\nAbout CollPlant\nCollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine. CollPlant recently entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market.\nFor more information, visit http://www.collplant.com.\nSafe Harbor Statements\nThis press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant's objectives plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often cha...